(+)-VINCRISTINE

Refractory Solid Tumors

Theodore LaetschSmall moleculePhase 1/2Active

CCC

55/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 44/ 100
Competitive Position: 89/ 100

Competitive context

7 Active assets in the Refractory Solid Tumors cohort.

Asset / Sponsor	Phase	Rating
Rapamycin Samsung Medical Center	Phase 4	BB
su011248 Samsung Medical Center	Phase 4	BB
Hydralazine National Institute of Cancerología	Phase 2	B
Valproic Acid National Institute of Cancerología	Phase 2	B
Irinotecan M.D. Anderson Cancer Center	Phase 1	CCC

View all 36 →

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant

BBB

Indicative ·

78 / 100

mycosis fungoidesDormant

BBB

Indicative ·

78 / 100

adult acute lymphoblastic leukemiaDormant

BBB

Indicative ·

77 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.